Oral Genome, a leading innovator in saliva testing, today announced a strategic partnership with Henry Schein, the world’s largest provider of healthcare solutions for dental and medical offices.
This collaboration aims to bring Oral Genome’s advanced, point-of-care saliva testing technology to dental and medical offices nationwide, fostering the deep integration of oral health into overall healthcare.
Oral Genome’s saliva testing kits enable rapid, point-of-care testing, providing accurate results in under 15 minutes.
Combined with proprietary software, this technology analyzes key biomarkers in saliva in real time, enabling healthcare professionals to comprehensively monitor a patient’s oral and overall health.
Leveraging Henry Schein’s extensive distribution network, dental professionals can access critical health data instantly during their clinic visit, enabling early intervention and strengthening the doctor-patient relationship.
Dr. Tina Saw, CEO of Oral Genome, said, “We look forward to collaborating with Henry Schein to bridge the gap between dentistry and healthcare.
Our point-of-care testing technology provides clinicians with practical insights, transforming traditional oral care into a new opportunity for holistic health management.”
Dirk Benson, President of Henry Schein’s U.S. Distribution Group, added, “Henry Schein is committed to bringing cutting-edge solutions to our customers to improve patient outcomes.
The addition of Oral Genome’s point-of-care testing aligns with our mission to advance preventive and systemic health management, providing dentists and physicians with a powerful tool to support their care.”
This collaboration, which will be available through Henry Schein’s distribution channels to dental offices, community healthcare organizations, and healthcare providers seeking advanced preventive technologies, demonstrates both companies’ unwavering commitment to advancing healthcare through technological innovation and collaboration.
